Resources
72 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/27/2019 (updated 3/28/2024)
Negative language and stigma regarding substance use disorder and addiction have shown to be a key barrier to seeking and receiving treatment for people who use drugs.
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 2/25/2020 (updated 3/28/2024)
A guide to provide the addiction treatment and recovering community with practical information and tools to enhance their capacity to engage in effective stigma reduction efforts.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Capitol Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 4/16/2020 (updated 3/28/2024)
Stigma keeps people from the best possible care. Beyond Labels is a free Anti-Stigma Toolkit for Women & Babies toolkit from the March of Dimes and RTI International.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 9/30/2020 (updated 3/29/2024)
This page offers background information and tips for providers to keep in mind while using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.